The agreement allows for an equity-sparing, stepping up the pace of development of Cardiovascular Sciences’s anti-adhesion technology and allows Medical Technologies Enterprises’s access to and early entry into markets with needs addressed by this technology and other related technologies.
Larry Hooper, CEO of Cardiovascular Sciences, said: “Initially, there will be an economy resulting from sharing many of the administrative operations of the two companies. Second, it gives us a retail presence in the marketplace and on the web. It is seldom that a company, at this stage in the development of its primary medical technology, has revenue generating retail market presence.”